Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

Shares of Cytosorbents Corporation (NASDAQ:CTSO) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.77 and traded as high as $0.7989. Cytosorbents shares last traded at $0.7250, with a volume of 39,671 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, January 9th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 12th. Finally, HC Wainwright decreased their price objective on shares of Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Cytosorbents presently has an average rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Price Performance

The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 1.61. The stock has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.77. The stock has a market capitalization of $45.53 million, a price-to-earnings ratio of -4.03 and a beta of 1.36.

Institutional Trading of Cytosorbents

Institutional investors have recently made changes to their positions in the stock. Avenir Corp increased its stake in Cytosorbents by 0.3% in the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after buying an additional 13,619 shares during the period. Citadel Advisors LLC boosted its stake in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares during the period. CM Management LLC grew its holdings in shares of Cytosorbents by 3.1% during the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after acquiring an additional 38,128 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.